Karyopharm Therapeutics Inc (KPTI) Analysis & Forecast for 2023

Karyopharm Therapeutics Inc (NASDAQ: KPTI) is -75.76% lower on its value in year-to-date trading and has touched a low of $0.62 and a high of $4.87 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KPTI stock was last observed hovering at around $0.76 in the last trading session, with the day’s gains setting it 0.06% off its average median price target of $5.00 for the next 12 months. It is also 91.8% off the consensus price target high of $10.00 offered by 9 analysts, but current levels are 72.67% higher than the price target low of $3.00 for the same period.

Currently trading at $0.82, the stock is 5.87% and -1.87% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.36 million and changing 8.34% at the moment leaves the stock -56.95% off its SMA200. KPTI registered -72.81% loss for a year compared to 6-month loss of -56.86%. The firm has a 50-day simple moving average (SMA 50) of $0.44 and a 200-day simple moving average (SMA200) of -$0.55.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The stock witnessed a 15.96% gain in the last 1 month and extending the period to 3 months gives it a -31.33%, and is 6.34% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.37% over the week and 12.89% over the month.

Karyopharm Therapeutics Inc (KPTI) has around 385 employees, a market worth around $94.37M and $145.87M in sales. Profit margin for the company is -95.82%. Distance from 52-week low is 33.46% and -83.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-188.94%).

Karyopharm Therapeutics Inc (KPTI) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Karyopharm Therapeutics Inc (KPTI) is a “Overweight”. 9 analysts offering their recommendations for the stock have an average rating of 1.89, where 3 rate it as a Hold and 2 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Karyopharm Therapeutics Inc is expected to release its quarterly report on 02/15/2024.The EPS is expected to grow by 43.45% this year.

Karyopharm Therapeutics Inc (KPTI) Top Institutional Holders

The shares outstanding are 113.21M, and float is at 106.43M with Short Float at 17.41%.

Karyopharm Therapeutics Inc (KPTI) Insider Activity

A total of 11 insider transactions have happened at Karyopharm Therapeutics Inc (KPTI) in the last six months, with sales accounting for 10 and purchases happening 1 times. The most recent transaction is an insider sale by Paulson Richard A.,the company’sPresident and CEO. SEC filings show that Paulson Richard A. sold 3,622 shares of the company’s common stock on Dec 04 at a price of $0.79 per share for a total of $2861.0. Following the sale, the insider now owns 0.79 million shares.

Karyopharm Therapeutics Inc disclosed in a document filed with the SEC on Nov 06 that Paulson Richard A. (President and CEO) sold a total of 3,606 shares of the company’s common stock. The trade occurred on Nov 06 and was made at $0.92 per share for $3319.0. Following the transaction, the insider now directly holds 0.79 million shares of the KPTI stock.

Still, SEC filings show that on Oct 04, Paulson Richard A. (President and CEO) disposed off 3,589 shares at an average price of $1.27 for $4558.0. The insider now directly holds 794,807 shares of Karyopharm Therapeutics Inc (KPTI).

Karyopharm Therapeutics Inc (KPTI): Who are the competitors?

The company’s main competitors (and peers) include Bristol Myers Squibb Co. (BMY) that is trading -28.26% down over the past 12 months. Abbott Laboratories (ABT) that is 0.79% higher over the same period.